Article | January 26, 2024

Defining "Evidence Generation" Within Modern Clinical Trials

Source: Medable

By Colin Weller, General Manager, Platform and Digital Solutions

GettyImages-1368237809 data

In the clinical research industry, tools like Digital Biomarkers and Endpoints are transforming evidence generation. A recent NIH-published study highlights the regulatory qualification of a digital measure of ambulation, SV95C, setting a crucial precedent for wearable technology in Duchenne Muscular Dystrophy trials. This qualification may reduce sample sizes by up to 70%, positively impacting cost, timelines, insights, and compliance. The potential to cut patient recruitment durations addresses a leading cause of trial delays, mitigating revenue loss and reducing the burden on participants in drug development and clinical research.

Our platform, centered on enabling clinical trial sponsors to gather data and generate evidence, stands out for its unique flexibility, purpose, and structure, with clients noting that they appreciate the adaptability in deploying standard solutions tailored to their trials, fostering participant engagement regardless of location. Learn more about how this distinctive approach, coupled with choice and flexibility, ensures a user-friendly, scalable platform successful in acquiring diverse data.

access the Article!

Get unlimited access to:

Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue. X

Enter your credentials below to log in. Not yet a member of Clinical Leader? Subscribe today.

Subscribe to Clinical Leader X

Please enter your email address and create a password to access the full content, Or log in to your account to continue.


Subscribe to Clinical Leader